Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration

Oncogene

Volumn 34, Issue 24, 2015, Pages 3095-3106

  Mi, W ^a   Lin, Q ^a,b   Childress, C ^a   Sudol, M ^a,c   Robishaw, J ^a   Berlot, C H ^a   Shabahang, M ^d   Yang, W ^a  

^a WEIS CENTER FOR RESEARCH   (United States)

^b JIANGSU UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; FARNESOL; GERANYLGERANIOL; GGTI 298; LAT PROTEIN; PROTEIN; PROTEIN LATS1; PROTEIN MST1; PROTEIN MST2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SQUALENE; UBIQUINONE; UNCLASSIFIED DRUG; BENZAMIDES; HEPTANOIC ACIDS; HIPPO PROTEIN, HUMAN; PROTEIN-SERINE-THREONINE KINASES; PYRROLES;

ARTICLE; BREAST CANCER CELL LINE; CARCINOGENESIS; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FARNESYLATION; GENE EXPRESSION; GERANYLGERANYLATION; GLYCATION; HEK293 CELL LINE; HIPPO PATHWAY; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BREAST NEOPLASMS; CELL MOVEMENT; DRUG EFFECTS; FEMALE; HEK293 CELLS; HUMANS; MCF-7 CELLS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR CELLS, CULTURED;

BENZAMIDES; BREAST NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HEK293 CELLS; HEPTANOIC ACIDS; HUMANS; MCF-7 CELLS; PRENYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PYRROLES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84930925114     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.251     Document Type: Article

References (62)

1. Reid TS, Terry KL, Casey PJ, Beese LS. Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol 2004; 343: 417-433.
2. Yokoyama K, Goodwin GW, Ghomashchi F, Glomset JA, Gelb MH. A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. Proc Natl Acad Sci USA 1991; 88: 5302-5306.
3. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-535.
4. Lim KH, Baines AT, Fiordalisi JJ, Shipitsin M, Feig LA, Cox AD et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005; 7: 533-545.
5. Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature 1998; 394: 295-299.
6. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 1990; 87: 3042-3046.
7. Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011; 11: 775-791.
8. Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 2007; 40: 575-584.
9. Cuello FM, Kato CS, Diaz SD, Owen G. Effects of statins in cancer. Rev Med Chil 2013; 141: 227-236.
10. Onono F, Subramanian T, Sunkara M, Subramanian KL, Spielmann HP, Morris AJ. Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathway. J Biol Chem 2013; 288: 27444-27455.
11. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 1999; 274: 21926-21931.
12. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22: 1139-1148.
13. Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW et al. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Res Treat 2014; 143: 301-312.
14. Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity. J Biol Chem 1999; 274: 6930-6934.
15. Dan HC, Jiang K, Coppola D, Hamilton A, Nicosia SV, Sebti SM et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004; 23: 706-715.
16. Falsetti SC, Wang DA, Peng H, Carrico D, Cox AD, Der CJ et al. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol 2007; 27: 8003-8014.
17. Vogt A, Sun J, Qian Y, Hamilton AD, Sebti SM. The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 1997; 272: 27224-27229.
18. Sjogren AK, Andersson KM, Liu M, Cutts BA, Karlsson C, Wahlstrom AM et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 2007; 117: 1294-1304.
19. Vogt A, Qian Y, McGuire TF, Hamilton AD, Sebti SM. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene 1996; 13: 1991-1999.
20. Budman DR, Tai J, Calabro A. Fluvastatin enhancement of trastuzumab and classical cytotoxic agents in defined breast cancer cell lines in vitro. Breast Cancer Res Treat 2007; 104: 93-101.
21. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E et al. Breast cancer growth prevention by statins. Cancer Res 2006; 66: 8707-8714.
22. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat 2010; 119: 137-144.
23. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 2007; 21: 2747-2761.
24. Zhang H, Liu CY, Zha ZY, Zhao B, Yao J, Zhao S et al. TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem. 2009; 284: 13355-13362.
25. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150: 780-791.
26. Ahmed SM, Daulat AM, Meunier A, Angers S. G protein betagamma subunits regulate cell adhesion through Rap1a and its effector Radil. J Biol Chem 2010; 285: 6538-6551.
27. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem. 2004; 92: 949-966.
28. Xiang SY, Dusaban SS, Brown JH. Lysophospholipid receptor activation of RhoA and lipid signaling pathways. Biochim Biophys Acta 2013; 1831: 213-222.
29. Lehmann DM, Seneviratne AM, Smrcka AV. Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation. Mol Pharmacol 2008; 73: 410-418.
30. Saini DK, Kalyanaraman V, Chisari M, Gautam N. A family of G protein betagamma subunits translocate reversibly from the plasma membrane to endomembranes on receptor activation. J Biol Chem 2007; 282: 24099-24108.
31. Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012; 26: 54-68.
32. Solski PA, Helms W, Keely PJ, Su L, Der CJ. RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification. Cell Growth Differ 2002; 13: 363-373.
33. Justice RW, Zilian O, Woods DF, Noll M, Bryant PJ. The Drosophila tumor suppressor gene warts encodes a homolog of human myotonic dystrophy kinase and is required for the control of cell shape and proliferation. Genes Dev 1995; 9: 534-546.
34. Xu T, Wang W, Zhang S, Stewart RA, Yu W. Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 1995; 121: 1053-1063.
35. Park HW, Guan KL. Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci 2013; 34: 581-589.
36. Sudol M, Shields DC, Farooq A. Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin Cell Dev Biol 2012; 23: 827-833.
37. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 2012; 109: E2441-E2450.
38. Zhao B, Tumaneng K, Guan KL. The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nat Cell Biol 2011; 13: 877-883.
39. Zhao B, Ye X, Yu J, Li L, Li W, Li S et al. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 2008; 22: 1962-1971.
40. Benhamouche S, Curto M, Saotome I, Gladden AB, Liu CH, Giovannini M et al. Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. Genes Dev 2010; 24: 1718-1730.
41. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 2006; 103: 12405-12410.
42. Hill VK, Dunwell TL, Catchpoole D, Krex D, Brini AT, Griffiths M et al. Frequent epigenetic inactivation of KIBRA, an upstream member of the Salvador/Warts/Hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia. Epigenetics 2011; 6: 326-332.
43. Song M, Cheong JH, Kim H, Noh SH, Kim H. Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Res 2012; 32: 3827-3834.
44. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008; 39: 1582-1589.
45. Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. Oncogene 2011; 30: 2810-2822.
46. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 2008; 68: 2592-2598.
47. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X et al. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci USA 2014; 111: E89-E98.
48. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014; 16: 357-366.
49. Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol 2013; 8: 277-302.
50. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005; 7: 17-23.
51. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458.
52. Kubatka P, Zihlavnikova K, Kajo K, Pec M, Stollarova N, Bojkova B et al. Antineoplastic effects of simvastatin in experimental breast cancer. Klin Onkol 2011; 24: 41-45.
53. Shibata MA, Ito Y, Morimoto J, Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 2004; 25: 1887-1898.
54. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 2008; 17: 1028-1033.
55. Tang X, Sun Z, Runne C, Madsen J, Domann F, Henry M et al. A critical role of Gbetagamma in tumorigenesis and metastasis of breast cancer. J Biol Chem 2011; 286: 13244-13254.
56. Smrcka AV. G protein subunits: central mediators of G protein-coupled receptor signaling. Cell Mol Life Sci 2008; 65: 2191-2214.
57. Kirui JK, Xie Y, Wolff DW, Jiang H, Abel PW, Tu Y. Gbetagamma signaling promotes breast cancer cell migration and invasion. J Pharmacol Exp Ther 2010; 333: 393-403.
58. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68: 8022-8030.
59. Oka T, Mazack V, Sudol M. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). J Biol Chem 2008; 283: 27534-27546.
60. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2007; 2: 329-333.
61. Mi W, Gu Y, Han C, Liu H, Fan Q, Zhang X et al. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim Biophys Acta 2011; 1812: 514-519.
62. Shen F, Lin Q, Gu Y, Childress C, Yang W. Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol Biol Cell 2007; 18: 732-742.